Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Somatically mutated ABL1 is an actionable and essential NSCLC survival gene

12 Jan 2016

Abstract excerpt

The lack of actionable mutations in patients with non-small cell lung cancer (NSCLC) presents a significant hurdle in the design of targeted therapies for this disease. Here, we identify somatically mutated ABL1 as a genetic dependency that is required to maintain NSCLC cell survival. We demonstrate that NSCLC cells with ABL1 mutations are sensitive to ABL inhibitors and we verify that the drug-induced effects on...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Chronic Lymphocytic Leukemia Research
Share to Chronic Myeloid Leukemia Treatments
Share to PI3K/AKT/mTOR signaling in cancer

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 26758680
DOI: 10.15252/emmm.201505456

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 6 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 10 closest

Somatically mutated ABL1 is an actionable and essential NSCLC survival genePMID 26758680Read ↗

Structure, Regulation, Signaling, and Targeting of Abl Kinases in CancerSemantic proximity Read ↗

The capable ABL: what is its biological function?Semantic proximity Read ↗

mTOR dependent transformed human cells have a distinct set of essential genes from bcr-abl transformed cellsSemantic proximity Read ↗

Crizotinib acts as ABL1 inhibitor combining ATP-binding with allosteric inhibition and is active against native BCR-ABL1 and its resistance and compound mutants BCR-ABL1T315I and BCR-ABL1T315I-E255K.Semantic proximity Read ↗

Imatinib sensitivity in BCR-ABL1-positive chronic myeloid leukemia cells is regulated by the remaining normal ABL1 allele.Semantic proximity Read ↗

Activated Abl kinase inhibits oncogenic transforming growth factor‐β signaling and tumorigenesis in mammary tumorsSemantic proximity Read ↗

Elevated BCRP/ABCG2 Expression Confers Acquired Resistance to Gefitinib in Wild-Type EGFR-Expressing CellsSemantic proximity Read ↗

Phosphorylation of BECLIN-1 by BCR-ABL suppresses autophagy in chronic myeloid leukemiaSemantic proximity Read ↗

Enhancement of ABL kinase catalytic efficiency by a direct binding regulator is independent of other regulatory mechanisms.Semantic proximity Read ↗

Autophosphorylation of the oncogenic protein TEL-ABL confers resistance to the allosteric ABL inhibitor asciminibSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.